Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2014

01-09-2014 | Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Diabetic Gastroparesis: Functional/Morphologic Background, Diagnosis, and Treatment Options

Authors: Viktor J. Horváth, Ferenc Izbéki, Csaba Lengyel, Péter Kempler, Tamás Várkonyi

Published in: Current Diabetes Reports | Issue 9/2014

Login to get access

Abstract

The regulation of gastrointestinal motility mainly involves the smooth muscle, neural (extrinsic and intrinsic), and hormonal elements, the glial cells, and the interstitial cells of Cajal. An orchestrated function of all these components is required for the appropriate propulsive movement of the food in the gastrointestinal tract. Gastroparesis, a pathological slowing-down of gastric emptying, is a result of the damage to the tissue elements involved in the regulation of motility. Gastroparesis is one of the well-known complications of long-standing diabetes mellitus. Although it is rarely a life-threatening complication, it has a deteriorating effect on the quality of life, leads to unpredictable oscillation of the blood glucose level, and increases the time required for the absorption of food and medicines. This review describes the clinical characteristics of diabetic gastroparesis and summarizes the organic and functional motility abnormalities caused by this complication. Finally, the currently available and potential future therapeutic approaches are summarized.
Literature
1.
2.
O'Grady G et al. Origin and propagation of human gastric slow-wave activity defined by high-resolution mapping. Am J Physiol Gastrointest Liver Physiol. 2010;299(3):585–2.CrossRef
3.
Wood JD. Neurogastroenterology and motility. In: Rhoades RA, Bell DR, editors. Principles of medical phisiology. 3rd edn. LWW; 2009. pp. 483–6.
4.
5.
Rundles RW. Diabetic neuropathy: general review with report of 125 cases. Medicine. 1945;24:111–60.CrossRef
6.
Soykan I et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–404.PubMedCrossRef
7.
Feldman M et al. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378–84.PubMedCrossRef
8.
9.
Jones KL et al. Predictors of delayed gastric emptying in diabetes. Diabetes Care. 2001;24:1264–9.PubMedCrossRef
10.
Barucha AE et al. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol (Oxf). 2009;70(3):415–20.CrossRef
11.
12.
13.
14.
Revicki DA et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–50.PubMedCrossRef
15.
De la Loge C et al. Cross-cultural development and validation of a self-administered questionnaire to assess quality of life in upper gastrointestinal disorders. Qual Life Res. 2004;13:1751–62.PubMedCrossRef
16.
Bytzer P et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med. 2001;161:1989–96.PubMedCrossRef
17.
Hasler WL. Type 1 diabetes and gastroparesis: diagnosis and treatment. Curr Gastroenterol Rep. 2007;9:261–9.PubMedCrossRef
18.
Ordog T. Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol Motil. 2008;20:8–18.PubMedCrossRef
19.
Intagliata N et al. Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment. Curr Gastroenterol Rep. 2007;9:270–9.PubMedCrossRef
20.
Watkins CC et al. Insulin restores neuronal nitric oxide synthase expression and function that lost in diabetic gastropathy. J Clin Invest. 2000;106(3):373–84.PubMedCentralPubMedCrossRef
21.
22.
Kong MF et al. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin Geriatr Med. 1999;15:321–38.PubMed
23.
Koch KL et al. Diabetic gastroparesis: comparison of clinical features in patients with Type 2 (T2DM) and Type 1 (T1DM) diabetes mellitus [abstract]. Am J Gastroenterol. 2009;104(Suppl3):S56.
24.
Izbéki F et al. The clinical picture, diagnosis and therapy of gastrointestinal autonomic neuropathy. In: Kempler P, Várkonyi T, editors. Neuropathies. A global clinical guide. Budapest: Zafír Press - Mona Lib Kft; 2012. p. 131–50.
25.
MacGregor IL et al. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology. 1976;70:190–6.PubMed
26.
Jebbink RJ et al. Hyperglycaemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology. 1994;107(5):1994–9.
27.
Horváth VJ et al. Reduced insulin and IGF-I signaling, not hyperglycemia, underlies the diabetes-associated depletion of interstitial Cells of cajal in the murine stomach. Diabetes. 2005;54:1528–33.PubMedCrossRef
28.
Schvarcz E et al. Physiological hyperglycaemia slows gastric emptying in normal subjects and in patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1):60–6.PubMedCrossRef
29.
Vittal H et al. Mechanisms of disease: the pathological basis of gastroparesis–a review of experimental and clinical studies. Nat Clin Pract Gastroenterol Hepatol. 2007;4(6):336–46.PubMedCrossRef
30.
Camilleri M et al. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986;91:94–9.PubMed
31.
32.
Parkman HP et al. American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–622.PubMedCrossRef
33.
Nishikawa T et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.PubMedCrossRef
34.
Choi KM et al. Differences in protein expression between diabetic NOD mice with and without delayed gastric emptying. Gastroenterology. 2007;132:A-112.
35.
Choi KM et al. Regulation of interstitial cells of Cajal in the mouse gastric body by neuronal nitric oxide. Neurogastroenterol Motil. 2007;19:585–95.PubMedCrossRef
36.
Harberson J et al. Gastric neuromuscular pathology in gastroparesis: analysis of full-thickness antral biopsies. Dig Dis Sci. 2010;10:359–70.CrossRef
37.
Grover M et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil. 2012;24(6):531–40.PubMedCrossRef
38.
39.
Gover M, NIDDK Gastroparesis Clinical Research Consortium, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. 2011;140(5):1575–85.CrossRef
40.
Horváth VJ et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of Cajal in murine diabetic gastroparesis. Gastroenterology. 2006;130(3):759–70.PubMedCrossRef
41.
Wu JJ et al. Development of the interstitial cell of Cajal: origin, kit dependence and neuronal and nonneuronal sources of kit ligand. J Neurosci Res. 2000;59(3):384–401.PubMedCrossRef
42.
43.
Izbeki F et al. Loss of Kitlow progenitors, reduced stem cell factor and high oxidative stress underlie gastric dysfunction in progeric mice. J Physiol. 2010;588(16):3101–7.PubMedCentralPubMedCrossRef
44.
Kempler P et al. On behalf of the Toronto Consensus Panel on Diabetic Neuropathy Gastrointestinal autonomic neuropathy, erectile-, bladder- and sudomotor dysfunction in patients with diabetes mellitus: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27:665–77.CrossRef
45.
46.
Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat Rev Gastroenterol Hepatol. 2011;8(8):438–53.PubMedCrossRef
47.
Bolinder J et al. Autonomic neuropathy is associated with impaired pancreatic polypeptide and neuropeptide Y responses to insulin-induced hypoglycaemia in Type I diabetic patients. Diabetologia. 2002;45(7):1043–4.PubMedCrossRef
48.
Kempler P, EURODIAB IDDM Complications Study Group, et al. Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med. 2002;19(11):900–9.PubMedCrossRef
49.
50.
Lam WF et al. Hyperglycemia reduces gastric secretory and plasma pancreatic polypeptide responses to modified sham feeding in humans. Digestion. 1993;54:48–53.PubMedCrossRef
51.
Yeap BB et al. Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects. Diabetes Care. 1996;19(8):880–2.PubMedCrossRef
52.
Várkonyi T et al. Manifestations of diabetic polyneuropathy in the digestive tract and the central nervous system. Diabetol Hung. 2002;10 suppl 2:44–50.
53.
Pavy-Le Traon A et al. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res. 2010;20(3):153–60.PubMedCrossRef
54.
Lelic D et al. The brain networks encoding visceral sensation in patients with gastrointestinal symptoms due to diabetic neuropathy. Neurogastroenterol Motil. 2014;26(1):46–58.PubMedCrossRef
55.
Brock C et al. Peripheral and central nervous contribution to gastrointestinal symptoms in diabetic patients with autonomic neuropathy. Eur J Pain. 2012;17:820–31.PubMedCrossRef
56.
Várkonyi T et al. Severity of autonomic and sensory neuropathy and the impairment of visual- and auditory-evoked potentials in type 1 diabetes. Is there a relationship? Diabetes Care. 2006;29:2325–6.PubMedCrossRef
57.
Punkkinen J et al. Upper abdominal symptoms in patients with Type 1 diabetes: unrelated to impairment in gastric emptying caused by autonomic neuropathy. Diabet Med. 2008;25(5):570–7.PubMedCrossRef
58.
59.
Chang J et al. Diabetic gastroparesis-backwards and forwards. J Gastroenterol Hepatol. 2011;26 Suppl 1:46–57.PubMedCrossRef
60.
Konturek JW et al. Effects of nitric oxide on antral motility and gastric emptying in humans. Eur J Gastroenterol Hepatol. 1995;7(2):97–102.PubMed
61.
Maner WL et al. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol. 2007;292:725–33.
62.
Micci MA et al. Neural stem cell transplantation in the stomach rescues gastric function in neuronal nitric oxide synthase-deficient mice. Gastroenterology. 2005;129(6):1817–24.PubMedCrossRef
63.
Pala L et al. Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions. Diabet Med. 2010;27(6):691–5.PubMedCrossRef
64.
Ariga H et al. Ghrelin accelerates gastric emptying via early manifestation of antro-pyloric coordination in conscious rats. Regul Pept. 2008;146(1–3):112–6.PubMedCrossRef
65.
Falkén Y et al. Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans. Neurogastroenterol Motil. 2010;22(6):192–200.CrossRef
66.
67.
Gaddipati KV et al. Abnormal ghrelin and pancreatic polypeptides responses in gastroparesis. Dig Dis Sci. 2006;51(8):1339–46.PubMedCrossRef
68.
Kan M et al. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy. J Neuropathol Exp Neurol. 2012;71(6):494–510.PubMedCrossRef
69.
Sam AH et al. Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology. 2012;143(2):459–69.PubMedCrossRef
70.
71.
72.
Aubé AC et al. Changes in enteric neurone phenotype and intestinal functions in a transgenic mouse model of enteric glia disruption. Gut. 2006;55(5):630–7.PubMedCentralPubMedCrossRef
73.
Abdo H et al. Enteric glial cells protect neurons from oxidative stress in part via reduced glutathione. FASEB J. 2010;24(4):1082–94.PubMedCrossRef
74.
75.
Abell TL et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008;36:44–54.PubMedCrossRef
76.
77.
Marzio L et al. Evaluation of the use of ultrasonography in the study of liquid gastric emptying. Am J Gastroenterol. 1989;84:496–500.PubMed
78.
Stevens JE et al. Measurement of gastric emptying of a high-nutrient liquid by 3D ultrasonography in diabetic gastroparesis. Neurogastroenterol Motil. 2011;23:220–5.PubMedCrossRef
79.
Olausson EA et al. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabetes Res Clin Pract. 2008;80:231–7.PubMedCrossRef
80.
Perkel MS et al. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig Dis Sci. 1979;24:662–6.PubMedCrossRef
81.
Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10–5.PubMedCrossRef
82.
Ricci DA et al. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol. 1985;7:25–32.PubMedCrossRef
83.
Henry P et al. Clinical response and side effects of metoclopramide associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46:494–503.CrossRef
84.
Strauss SM et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J. 2005;26:2007–12.CrossRef
85.
Lin HC et al. Erythromycin accelerates solid emptying at the expense of gastric sieving. Dig Dis Sci. 1994;39:124–8.PubMedCrossRef
86.
Moshiree B et al. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55(3):675–83.PubMedCrossRef
87.
Ray WA et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–96.PubMedCrossRef
88.
Várkonyi T et al. Diabetic neuropathy: new strategies for treatment. Diabetes Obes Metab. 2008;10:99–108.PubMed
89.
Ziegler D et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20(3):369–73.PubMedCrossRef
90.
Várkonyi T et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des. 2013;19(27):4981–5007.PubMedCrossRef
91.
Wo JM et al. Randomised clinical trial: ghrelin agonist TZP101 relieves gastroparesis associated with severe nausea and vomiting—randomised clinical study subset data. Aliment Pharmacol Ther. 2011;33:679–88.PubMedCrossRef
92.
Camilleri M et al. A ghrelin agonist fails to show benefit in patients with diabetic gastroparesis: let's not throw the baby out with the bath water. Neurogastroenterol Motil. 2013;25(11):859–63.PubMedCrossRef
93.
Chong K et al. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol. 2009;5:285–8.PubMedCrossRef
94.
Abell T et al. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology. 2003;125(2):421–8.PubMedCrossRef
95.
Kim KH et al. Acupuncture for symptomatic relief of gastroparesis in a diabetic haemodialysis patient. Acupunct Med. 2010;28:101–3.PubMedCrossRef
96.
Lin Z et al. Association between changes in symptoms and gastric emptying in gastroparetic patients treated with gastric electrical stimulation. Neurogastroenterol Motil. 2008;20:464–70.PubMedCrossRef
97.
Abell TL et al. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion. 2002;66:204–12.PubMedCrossRef
98.
McCallum RW et al. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology. 1998;114:456–61.PubMedCrossRef
99.
Fontana RJ et al. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol. 1996;91:2174–8.PubMed
Metadata
Title
Diabetic Gastroparesis: Functional/Morphologic Background, Diagnosis, and Treatment Options
Authors
Viktor J. Horváth
Ferenc Izbéki
Csaba Lengyel
Péter Kempler
Tamás Várkonyi
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0527-8

Other articles of this Issue 9/2014

Current Diabetes Reports 9/2014 Go to the issue

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Key Elements of Plant-Based Diets Associated with Reduced Risk of Metabolic Syndrome

Microvascular Complications—Neuropathy (D Ziegler, Section Editor)

Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

Metabolic Abnormalities in the Pathogenesis of Type 1 Diabetes

Psychosocial Aspects (KK Hood, Section Editor)

Young Children with Type 1 Diabetes: Challenges, Research, and Future Directions

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Multifocal Electroretinography in Diabetic Retinopathy and Diabetic Macular Edema

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Managing Sedentary Behavior to Reduce the Risk of Diabetes and Cardiovascular Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits